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ABSTRACT 
 
Title: Bilirubin lowering effect and safety of a prototype low cost blue light emitting diode (LED) 
phototherapy device in the treatment of indirect hyperbilirubinemia among healthy term infants 
in Ospital ng Makati: a pilot study. 
 
Background:  
Phototherapy is the most frequently used treatment for the control of neonatal jaundice. The 
rate of decline of total serum bilirubin level during phototherapy depends on several factors: 
type of phototherapy, type of light, irradiance level, surface area covered and initial total serum 
bilirubin level.  Light-emitting diodes (LEDs) are power-efficient, low heat-producing light 
sources that has the potential to deliver high intensity light of narrow wavelength band in the 
blue-green portion of the visible light spectrum, which overlaps the absorption spectrum of 
bilirubin resulting in potentially shorter treatment times. These characteristics make LEDs an 
optimal light source for phototherapy.  
 
Objective: This pilot study was done to evaluate the capability of a prototype low cost blue light 
emitting diode (LED) phototherapy device in lowering bilirubin levels among healthy term infants 
diagnosed with indirect hyperbilirubinemia.  
 
Methods: Experimental study on term infants diagnosed with indirect hyperbilirubinemia in 
Ospital ng Makati from May 2016 to November 2016 who underwent phototherapy using the low 
cost blue LED phototherapy prototype.  
Results:  After 24 hours of phototherapy under the prototype LED phototherapy unit, 16% of the 
total patients completed treatment as they were already classified in the low risk zone, and 
another 36% of patients completed treatment after 48 hours.  The total bilirubin significantly 
decreased from baseline bilirubin levels after 24 hours by 16.5% (p = 0.0001).  The mean 
percentage of change of bilirubin reduced after 48 hours of 29.9% was also significant.  The 
proportion of subjects in the high risk zone during baseline to 24th hour went down significantly 
from 80% to 28% (p = 0.0003), while comparing baseline to 48th hour, the percentage of high 
risk zone went down from 80% to 9.5% (p = 0.0001).  No subjects were reported to have 
rebound hyperbilirubinemia after discontinuation of phototherapy treatment under the LED 
prototype. No patient experienced any complication while on phototherapy treatment. 
Conclusion: The prototype low cost blue light emitting diode (LED) phototherapy was able to 
lower total serum bilirubin among healthy term infants with indirect hyperbilirubinemia and was 
safe to use.   
Keywords: neonatal jaundice, indirect hyperbilirubinemia, phototherapy, light emitting diode 
(LED) phototherapy 
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INTRODUCTION 
Jaundice is one of the most common conditions needing medical attention in newborn 
infants.  It is caused by a raised level of bilirubin in the body, a condition known as 
hyperbilirubinemia.  Neonatal jaundice occurs in 25% to 50% of term newborns, and in a larger 
proportion of preterm newborns, in the first two weeks of life.  Most jaundice is a benign 
transient physiological event in the majority of newborns.  Various mechanisms are involved in 
producing this 'physiological' increase in serum total bilirubin include increased production of 
bilirubin due to lysis of red blood cells, decreased ability of liver cells to clear bilirubin and 
increased enterohepatic circulation. Any condition that further increases bilirubin production or 
alters the transport or metabolism of bilirubin increases the severity of the physiological 
jaundice.1   Because of the potential toxicity of bilirubin which can cause permanent neurological 
disability, it is important to identify newborn infants who might develop severe 
hyperbilirubinemia.2   
Phototherapy is the most frequently used treatment when serum bilirubin levels exceed 
physiological limits. To initiate phototherapy without delay is the most important intervention for 
infants with severe hyperbilirubinemia.  Phototherapy converts bilirubin into water soluble photo-
products that can bypass the hepatic conjugating system and be excreted without further 
metabolism. The clinical response to phototherapy depends on the efficacy of the phototherapy 
device, as well as the infant’s rates of bilirubin production and elimination.3  
Phototherapy can be delivered using several types of conventional light sources, 
including daylight, white or blue fluorescent bulbs and filtered halogen bulbs.  The efficacy and 
ability of these light sources to provide intensive phototherapy varies widely and some may be 
limited because of the inability to keep them close to the infant due to high heat production and 
unstable broad wavelength light output. In recent years, a new type of light source, light-emitting 
diodes (LEDs) have been developed and studied as possible light sources for the phototherapy 
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of neonatal jaundice. LEDs are power efficient, portable devices with low heat production, light 
in weight and have a longer lifetime.1  Blue LEDs emit a high intensity narrow band of blue light 
overlapping the peak spectrum of bilirubin breakdown resulting in potentially shorter treatment 
times.  These characteristics of LEDs make them an optimal light sources for a phototherapy 
device.4   
 
REVIEW OF RELATED LITERATURE 
Jaundice is observed during the first week of life in approximately 60% of term infants 
and 80% or preterm infants.  It is a benign transient physiological event in the majority of 
newborns but can cause irreversible brain damage and kernicterus in some infants if the serum 
bilirubin levels are very high.5  Unconjugated hyperbilirubinemia in which the direct-reacting 
bilirubin level is less than 15% of serum total bilirubin is the most common form of jaundice seen 
in newborn infants. Common risk factors for pathological unconjugated hyperbilirubinemia 
include blood group incompatibility, glucose-6-phosphate dehydrogenase enzyme deficiency, 
prematurity, instrumental delivery and non-optimal breastfeeding.1 
Phototherapy is the standard treatment for neonatal jaundice.2 It converts bilirubin into 
water soluble photo-products that can bypass the hepatic conjugating system and be excreted 
without further metabolism.1  It uses irradiation with blue light to photoisomerize bilirubin into 
products that can be excreted in bile or urine.5  The clinical response to phototherapy depends 
on the efficacy of the phototherapy device, as well as the infant’s rates of bilirubin production 
and elimination. To initiate phototherapy without delay is the most important intervention for 
infants with severe hyperbilirubinemia.3  The efficacy of phototherapy is dependent upon 
wavelength, irradiance, exposed body surface area, distance of the phototherapy, and duration 
of exposure.  Intensive phototherapy is provided by use of high levels of irradiance in the 430 to 
490 nm band, usually 30 µW/cm2 per nm or higher delivered to as much of the infant's body 
surface area as possible.2 
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The commonly used light sources for providing phototherapy include blue fluorescent 
tubes, compact fluorescent tubes and halogen spotlights. The efficacy and ability of these light 
sources to provide intensive phototherapy may be limited because of the inability to keep them 
close to the infant due to high heat production and unstable broad wavelength light output. In 
recent years, a new type of light source, light-emitting diodes (LEDs) have been developed and 
studied as possible light sources for the phototherapy of neonatal jaundice. LEDs are power 
efficient, portable devices with low heat production so that they can be placed very close to the 
skin of the infants without any apparent untoward effects. They are also durable light sources 
with an average life span of 20, 000 hours hence with a low cost potential.1  Blue LEDs emit a 
high intensity narrow band of blue light overlapping the peak spectrum of bilirubin breakdown 
and has a higher delivered irradiance resulting in potentially shorter treatment times.  These 
characteristics of LEDs make them an optimal light sources for a phototherapy device.4  
Vreman et. al. in 1998 studied high intensity light-emitting diodes (LEDs) as possible 
light sources for the phototherapy of hyperbilirubinemic neonates.  They constructed a prototype 
phototherapy device using 300 blue LEDs and compared it with that of conventional 
phototherapy devices by measuring the in vitro photodegradation of bilirubin in human serum 
albumin.  The result of the study showed that the prototype device with three focused arrays, 
each with 100 blue LEDs, generated greater irradiance (> 200 microW.cm-2.nm-1) than any of 
the conventional devices tested and supported the greatest rate of bilirubin photodegradation: 
degrading bilirubin by 28% of dark control, followed by blue-green (18% of control), and then 
white light (14% of control) and least was green light (11% of control).  Hence it was concluded 
in the study that light from LED should be considered a more effective treatment for 
hyperbilirubinemia than light from other phototherapy devices used.6 
Kumar P, et. al conducted a systematic review on six randomized controlled trials in 
2010 that compared the efficacy of LED phototherapy to conventional phototherapy such as 
halogen light sources and compact fluorescent light sources in decreasing TSB levels and 
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duration of treatment in neonates with unconjugated hyperbilirubinemia. It was concluded in the 
study that LED light source phototherapy is as effective in decreasing TSB at rates that are 
similar to phototherapy with conventional light sources.1  
In a controlled trial conducted by Mohammadizadeh, et. al in 2012 on preterm infants 
hospitalized in neonatal intensive care unit who needed conventional phototherapy for 
uncomplicated indirect hyperbilirubinemia, neonates received phototherapy through devices 
with LEDs or special blue fluorescent tubes. The ‘rate of fall of bilirubin’ and ‘duration of 
phototherapy’ have been the two main outcomes investigated.  Treatment failure defined as the 
need for exchange blood transfusion or intensive phototherapy, side effects like temperature 
instability (hypothermia or hyperthermia), skin rash, and burns were also considered.  Results of 
the study showed that LED light source is as effective as fluorescent tubes for the phototherapy 
of preterm infants with indirect hyperbilirubinemia in terms of decreasing levels of bilirubin.  
However, the LEDs unit resulted in less frequent hyperthermia, compared to the conventional 
fluorescent group.7 
In another randomized controlled study of Colindres, et. al. in 2011, 45 preterm neonates 
requiring phototherapy were randomized to receive phototherapy using LED-based lights, 
conventional fluorescent blue lights or conventional halogen lights. The average rate of 
decrease of bilirubin levels was 0.047-0.037 mg/dl/hour, 0.055-0.056 mg dl/ hour and 0.057-
0.045 mg/dl/hour in the groups receiving conventional fluorescent blue light, conventional 
halogen light and LED phototherapy, respectively. The average duration of phototherapy 
treatment in the three groups was 108.8-85.9 h, 92.8-38.1 h, 110.4-42.6 h, respectively. In this 
study, LED phototherapy using simple, low-cost set of lights was as effective of conventional 
phototherapy.5 
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SIGNIFICANCE OF THE STUDY 
 This study aims to evaluate the safety and bilirubin lowering effect of phototherapy using 
a prototype low-cost light emitting diode (LED) lights in healthy term infants diagnosed with 
indirect hyperbilirubinemia.  Phototherapy, despite being the recommended standard of 
treatment for hyperbilirubinemia in newborns, may not be available in developing countries 
because the devices and replacement bulbs are often too expensive.8  The results of this study 
can help provide evidence on whether a prototype low cost blue LED phototherapy device is 
safe to use and is capable of lowering bilirubin levels, prior to undergoing a clinical trial.  This is 
a preliminary study prior to a randomized controlled trial to ascertain and quantify the capability 
of the device so that it can be use in resource-challenged institutions especially in developing 
countries. 
 
OBJECTIVES 
General: 
 To evaluate the effectiveness of a prototype low cost blue light emitting diode (LED) 
phototherapy device in lowering bilirubin levels among healthy term infants diagnosed with 
indirect hyperbilirubinemia.  
 
Specific: 
1. To measure the rate at which the total serum bilirubin (TSB) changes during the first 24 
to 48 hours under low cost blue LED phototherapy device. 
 
2. To determine the average change in bilirubin level using a prototype low cost blue LED 
phototherapy device. 
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3. To determine the occurrence of treatment failure among term infants under low cost blue 
LED phototherapy prototype device. 
	  
4. To identify the possible side effects of phototherapy using prototype low cost blue LED 
phototherapy device.	  
	  
METHODOLOGY 
 
STUDY DESIGN 
 Experimental study on term infants diagnosed with indirect hyperbilirubinemia admitted 
at the nursery, OB ward, and pediatric ward of Ospital ng Makati from May 2016 to November 
2016.  Infants who met the inclusion criteria for the study underwent phototherapy using the low 
cost blue LED phototherapy prototype.  Bilirubin levels were monitored, at most for 48 hours.  
 
INCLUSION/EXCLUSION CRITERIA 
Included in the this study were term infants, 37 to 42 completed weeks of gestation with 
weights appropriate for gestational age, who developed indirect hyperbilirubinemia needing 
phototherapy within the first 14 days of life. The need for phototherapy was based on the age of 
the infants in hours and serum total bilirubin that is considered high risk to high intermediate risk 
indirect hyperilirubinemia which is above the 75th percentile based on the hour specific 
normogram (Appendix B) but not exceeding a total serum bilirubin level of more than 25mg/dl.  
Infants included had normal physical examination findings and normal laboratory test results 
such as complete blood count, reticulocyte count, peripheral blood smear and Coomb’s test.  
Excluded from the study were infants with onset of jaundice during the first 24 hours after birth; 
with direct bilirubin levels more than 20% of total bilirubin; with evidence of hemolysis (positive 
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direct Coombs test); diagnosed with neonatal sepsis; who needed exchange transfusion at the 
time of enrollment; and those with congenital malformations.  
 
SAMPLE SIZE 
  Subjects were recruited consecutively as they were diagnosed and deemed eligible 
based on inclusion/exclusion criteria.  A total of 27 patients were recruited for this pilot study. 
The sample size was computed using the 24 hour decrease in bilirubin of the first 8 subjects 
that were enrolled in this study and the following conditions: power = 80%, alpha = 0.05, effect 
size = 1, standard deviation (SD) = 1.854.   
 
INTERVENTION 
Baseline characteristics such as sex, weight, age of gestation at birth, age at the start of 
phototherapy, feeding history, maternal blood type, patient’s blood type, cause of 
hyperbilirubinemia and baseline total serum bilirubin levels of qualified neonates were recorded. 
The study was explained to the parents prior to enrollment and an informed consent was 
obtained.  All infants enrolled in the study received phototherapy using the blue light emitting 
diode (LED) phototherapy.   
The prototype low cost LED phototherapy unit was custom made in collaboration with 
Ateneo Innovation Center, a non-profit research organization in Ateneo de Manila University 
under the School of Science and Engineering. The following specifications were used as guide 
in making of the prototype: light source using blue light emitting diode (LED) giving off light in 
the wavelength spectrum of 460 to 490-nm (blue-green light region) with peak spectral 
irradiance of >30uW/cm2/nm at a recommended treatment distance of 30 cm above the patient.   
The prototype low cost LED phototherapy was made using 20 pieces blue LED lamps, 
connected in parallel, for a total power rating of 60 W as shown in Figure 1.  A Spectro-Vis Plus 
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(Vernier) was used to determine the spectrum of the LED lamps.  The range of the emission 
spectrum was found to be 462.1-476.4 nm (Figure 2). This range falls within the most effective 
range (460-490 nm) for phototherapy.9   
	  	  	  	  	  	  	   	  
Figure	  1.	  Assembly	  of	  the	  20	  pieces	  of	  blue	  LED	  lamps.	  
	  
	  
Figure	  2.	  The	  Spectro-­‐Vis	  Plus	  used	  in	  determining	  the	  emission	  spectrum	  
 
The intensity of the LED lamp was 12W/m2, measured using a light intensity meter.  The 
calculated value of the irradiance was 84 µW/cm2 /nm. This value is almost three times higher 
than the minimum recommended irradiance (30 at µW/cm2 /nm) required for intensive 
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phototherapy at 1-m distance.9  Figure 3 shows the measurement of the intensity of the LED 
lamp.  The calculation of the irradiance is shown below. 
	  	  	  	  	  	  Irradiance = measured intensity (microwatt/ square cm) / range of wavelength 
  
                 Irradiance = {(12 W/ m2) * (106 µW / watt) * [(1 m2 /104cm2)]}               
                                                 / {476.4 nm– 462.1 nm} 
                                  = 84 µW /cm2/nm 
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	   	  
Figure	  3.	  Measurement	  of	  the	  intensity	  of	  the	  LED	  lamp	  
	   	  	  	  	  	  	  
The total power consumption of this prototype is 75 watts which is less than one fifth of 
the commercial phototherapy light (about 400 watts) that uses fluorescent tubes.  This prototype 
unit can also be powered by photovoltaic cells (solar panels).  For a 100-watt solar panel at 
four-hours of sunlight, it can operate for 5 hours with all light bulbs continuously switched on. It 
is designed in such a way that it can also operate at half power and twice the time. 
An internal continuous test-run was conducted with all the lamps turned on for 7-hours, 
24-hours, and 72-hours. There was no notable degradation of the quality of the lamp. 
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The unit was designed in such a way that the whole light casing can be tilted from side 
to side, the metallic pipe stand height can be adjusted, the whole unit can be rolled through its 
wheels for mobility/easy handling. Figures 5 and 6 shows the complete phototherapy 
equipment.  The total cost for the development of the prototype equipment was approximately 
PhP 20,000.00 
	  
Figure	  5.	  The	  casing	  of	  the	  light	  source	  
	  
            	  
Figure	  6.	  The	  complete	  phototherapy	  equipment	  
 Detailed description of the development of the prototype LED phototherapy unit, 
including the testing of the equipment and the safety precautions built into the phototherapy 
device prior its use for the study is further discussed in Appendix F.    
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Infants were exposed, completely unclothed with their eyes and genital regions properly 
covered, to continuous phototherapy for 24 hours only interrupted during feeding, cleaning, 
blood sampling, and turning to sides every 2 hours. The interruptions in phototherapy were 
monitored and mothers were instructed to write down the number and duration of interruptions 
such as breastfeeding, cleaning and blood extractions in a data collection form that was 
provided. Those who developed comorbidities including hospital-acquired infections while 
enrolled in the study were withdrawn from the study.  Phototherapy using the prototype blue 
LED phototherapy unit was done for 24 to 48 hours.  Infants, who after the first 24 hours of 
phototherapy showed an increase in total serum bilirubin were shifted to conventional 
phototherapy.  Subjects with no change in total serum bilirubin level after 24 hours continued to 
receive treatment using the prototype blue LED phototherapy for another 24 hours.  After 48 
hours of using the prototype blue LED phototherapy unit, subjects who required further 
phototherapy treatment were shifted to conventional phototherapy.    
Participants enrolled in the study were monitored daily by the nurse-in-charge, including 
daily weight, vital signs every 4 hours, urine output and occurrence of possible complications 
such as rashes, burns, diarrhea, and hypothermia or hyperthermia every shift.  Occurrence of 
such complications were managed accordingly: hydration for occurrence of diarrhea and 
hyperthermia, application of therapeutic ointments for rashes or burns and possible referral to 
other services such as Dermatology and Surgery as needed.   
Total serum bilirubin levels were obtained through blood extraction using peripheral 
venipuncture at baseline then every 24 hours thereafter upon exposure to phototherapy.  Serum 
bilirubin levels was analyzed in the laboratory of Ospital ng Makati using clinical chemistry 
analyzer Architect C4000 model by Abbott.    
When the infants’ total serum bilirubin level fell to the low intermediate risk level (below 
the 75th percentile of the nomogram or TSB < 14 mg/dl) they were observed for another 24 
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hours after discontinuation of phototherapy prior to discharge to ensure that there was no 
rebound hyperbilirubinemia.   
If subjects were noted to be again jaundiced 24 hours after discontinuation of 
phototherapy, total serum bilirubin levels were taken to determine rebound in the bilirubin level.  
Neonates with rebound bilirubin values greater than the 75th percentile or equal to the baseline 
total serum bilirubin levels on admission were again exposed to phototherapy but this time 
under conventional fluorescent phototherapy.   
 
OUTCOMES 
Primary outcome results include the average rate of change of the total serum bilirubin 
level (mg/dl per hour) during the first 24 hours and on the second day of phototherapy 
treatment.  The overall rate of decrease of bilirubin was calculated as initial bilirubin 
concentration minus final bilirubin concentration over total treatment time (24 to 48 hours).  
Secondary outcomes determine the occurrence of treatment failure which include increase in 
TSB levels after 24 hours or no change in TSB level after 48 hours of exposure under prototype 
low cost blue LED phototherapy and occurrence of possible side effects of phototherapy such 
as skin rash, burns, diarrhea dehydration, hypothermia and hyperthermia.  
 
ANALYSIS 
 Descriptive statistics such as mean and standard deviation (SD) were used to present the 
profile and total serum bilirubin of patients.  The mean bilirubin levels and average rate of 
decline of the total serum bilirubin level with + 1 standard deviation were analyzed. The 
proportion of neonates who developed treatment failure and complications to phototherapy 
intervention were determined.  In comparing the baseline bilirubin against the 24th and 48th hour 
bilirubin, paired t-test was used.  Chi square and fisher test were used in comparing the risk 
zone level between and baseline vs 24th and 48th hour.  Test of significance was at 5% level.  
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Medcalc statistical software was used to carry out the computations.    
   
ETHICAL CONSIDERATION 
A voluntary informed consent (Appendix A) was obtained from the parents or legal 
guardian of the subjects prior to their inclusion in the study.  Confidentiality of patients’ 
information was maintained at all times through data anonymity.  Only the investigator and 
those involved in data processing were given access to these records.  The study protocol was 
approved by the hospital research ethics committee. 
Subjects were monitored regularly, including daily weight, vital signs every 4 hours, urine 
output every shift, and occurrence of possible complications such as burns, temperature 
instability, dehydration, skin rashes and loose stools.  The prototype LED phototherapy unit was 
regularly checked and calibrated once a month. 	  
 
RESULTS  
Profile of Patients 
 Twenty seven patients were enrolled in this study however only 25 subjects were 
analyzed.  The 2 subjects were withdrawn from the study due to development of symptoms 
other than jaundice such as fair suck, fair activity, hypoglycemia and fever, which were 
attributed with neonatal sepsis.  These symptoms were noted after they have completed 48th 
hour of phototherapy under the LED prototype. 
Of the 25 infants, 13 were males and 12 were females.  Analyzed infants have an 
average age of gestation of almost 39 weeks (38.5 ± 1.0), with mean gestational age upon 
admission of 5 days (5.4 ± 2.1), with mean weight of 3 kg (3.1 ± 0.4).  Subjects were mostly 
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blood type O (36%) while the least type was blood type AB.  Same pattern can be observed in 
terms of maternal blood type, where Type O is the most common.  In term of diagnosis, 52% 
were with breastfeeding jaundice, 36% with ABO incompatibility, mostly OA setup and 12% with 
breastmilk jaundice.  All patients were exclusively breastfeeding.  Seventeen subjects (68%) 
were supplemented with intravenous fluid.  The mean total serum bilirubin (TSB) of subjects 
upon admission was 19 mg/dl (19.72 ± 2.93)	  corresponding above the 95th percentile track (high 
risk zone) on the hour specific bilirubin nomogram. 
Table	  1.	  Demographic	  and	  Clinical	  Data	  of	  Patients	  (N=25)	  
Age	  of	  Gestation	  (weeks),	  mean	  ±	  sd	   38.5	  ±	  1.0	  
Age	  of	  Baby	  (days),	  mean	  ±	  sd	   5.4	  ±	  2.1	  
Gender,	  n,	  %	   	  
	  Female	   12	  (48.0)	  
	  Male	   13	  (52.0)	  
Weight	  (kg),	  mean	  ±	  sd	   3.1	  ±	  0.4	  
Blood	  Type,	  n,	  %	   	  
	  A	   7	  (28.0)	  
	  B	   8	  (32.0)	  
	  O	   9	  (36.0)	  
	  AB	   1	  (4.0)	  
Maternal	  Blood	  Type,	  n,	  %	   	  
	  A	   3	  (12.0)	  
	  B	   3	  (12.0)	  
	  O	   18	  (72.0)	  
	  AB	   1	  (4.0)	  
Diagnosis,	  n,	  %	   	  
Breastfeeding	  jaundice	   13	  (52.0)	  
Breastmilk	  jaundice	   3	  (12.0)	  
ABO	  incompatibility	   9	  (36.0)	  
	  	  	  	  	  	  	  	  OA	  set-­‐up	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  6	  (24.0)	  
	  	  	  	  	  	  	  	  OB	  set-­‐up	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3	  (12.0)	  
Breastfeeding,	  n,	  %	   25	  (100.0)	  
With	  intravenous	  fluid,	  n,	  %	   17	  (68.0)	  
Without	  intravenous	  fluid,	  n,	  %	   8	  (32.0)	  
Baseline	  TSB	  (mg/dl),	  mean	  ±	  sd	   19.72	  ±	  2.93	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Outcome of Treatment 
Table 2 show that after 24 hours of phototherapy under the prototype LED phototherapy 
unit, 16% of the total patients already completed treatment as they were already classified in the 
low risk zone, while another 36% of the patients completed treatment after 48 hours.  Overall, 
after 48 hours, 52% of infants completed phototherapy treatment.  However, 48% of subjects 
still needed further treatment after 48 hours of exposure under the LED phototherapy light, most 
of these patients had baseline total serum bilirubin > 20 mg/dl.  Subjects who completed 
phototherapy after the 24th and 48th hours were all discharged with good general condition. No 
subjects were reported to have rebound hyperbilirubinemia after discontinuation of phototherapy 
treatment under the LED prototype.   
Table	  2.	  Overall	  outcome	  of	  treatment	  
	  	   Number	  of	  subjects,	  n	  (%)	  
Completed	  treatment	  after	  24	  hours	   4	  (16.0)	  
Completed	  treatment	  after	  48	  hours	   9	  (36.0)	  
Continued	  treatment	  after	  48	  hours	  	   12	  (48.0)	  
 
Comparison on the Total Serum Bilirubin 
Considering all patients whether they have received intravenous fluid (IVF) or not, the 
mean decrease in bilirubin on the 24th hour was 3.25 ± 2.38, with percentage change of 16.5% 
(p = 0.0001).  This means that the amount of total bilirubin reduced after 24 hours of treatment 
under LED prototype was already significantly lower than the baseline.  Likewise, the mean 
percentage of decrease of bilirubin after 48 hours of 29.9% was also significant when compared 
to baseline (p = 0.0001). Moreover, the percentage of change from 24th to 48th hour of 18.9% 
was also significant (p = 0.0001). 
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Among 17 patients supplemented with intravenous fluid while on phototherapy, the 
percentage of decrease of 18.4% (p = 0.0001) from baseline to 24th hour was significant.  
Likewise, the 30.4% decrease in total bilirubin reduced after the 48th hour was also significant. 
Lastly, the percentage of change from 24th hour to 48th hour was also significant (17.5%). 
Table	  4.	  Change	  in	  TSB	  from	  baseline	  vs	  24th	  and	  48th	  hour	  among	  patients	  with	  IVF	  
With	  IVF	   Mean±	  SD	   p	  value	   Mean	  Difference±SD	   %	  Change	  (95%	  CI)	  
Baseline	  (n=17)	   21.15	  ±	  2.39	  
0.0001	   3.89	  ±	  2.42	   18.4%	  (12.5%	  to	  24.3%)	  
24th	  Hour	  (n=17)	   17.26	  ±	  3.26	  
	  
Baseline	  (n=14)	   21.15	  ±	  2.39	  
0.0001	   6.44	  ±	  2.91	   30.4%	  (22.5%	  to	  38.4%)	  
48th	  Hour	  (n=14)	   15.18	  ±	  2.82	  
	  
24th	  Hour	  (n=21)	   18.4	  ±	  2.24	  
0.0001	   3.22	  ±	  1.65	   17.5%	  (12.3%	  to	  22.7%)	  
48th	  Hour	  (n=14)	   15.18	  ±	  2.82	  
 
For the 8 patients without IVF, the mean decrease in bilirubin was 1.88 + 1.71 (p = 
0.0086) which indicates that the percentage of change of 11.3% from baseline to 24th hour was 
significant. Likewise, the 28.6% total bilirubin reduced after 48 hours was also significant. And 
lastly, the percentage of change from 24th hour to 48th hour was also significant (17.6%).	  
Table	  3.	  Change	  in	  total	  serum	  bilirubin	  (TSB)	  from	  baseline	  vs	  24th	  and	  48th	  hour	  
	  TSB	   Mean	  ±	  SD	   p	  value	   Mean	  Difference	  ±SD	   %	  Change	  (95%	  CI)	  
Baseline	  (n=25)	   19.72	  ±	  2.93	  
0.0001	   	  3.25	  ±	  2.38	   16.5%	  (11.5%	  to	  21.5%)	  
24th	  Hour	  (n=25)	   16.47	  ±	  3.10	  
	  
Baseline	  (n=21)	   19.72	  ±	  2.93	  
0.0001	   5.89	  ±	  2.71	   29.9%	  (23.6%	  to	  36.2%)	  
48th	  Hour	  (n=21)	   14.12	  ±	  2.98	  
	  
24th	  Hour	  (n=21)	   17.42	  ±	  2.32	  
0.0001	   3.30	  ±	  1.72	   18.9%	  (14.5%	  to	  23.5%)	  
48th	  Hour	  (n=21)	   14.12	  ±	  2.98	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Table	  5.	  Change	  in	  TSB	  from	  baseline	  vs	  24th	  and	  48th	  hour	  among	  patients	  without	  IVF	  
Without	  IVF	   Mean	  ±	  SD	   p	  value	   Mean	  Difference	  ±	  SD	   %	  Change	  (95%	  CI)	  
Baseline	  (n=8)	   16.66	  ±	  0.84	  
0.0086	   1.88	  ±	  1.71	   11.3%	  (2.7%	  to	  19.8%)	  
24th	  Hour	  (n=8)	   14.79	  ±	  2.01	  
	  	  
Baseline	  (n=7)	   16.80	  ±	  0.80	   	  
0.0004	   4.8	  ±	  2.02	   28.6%	  (17.4%	  to	  39.7%)	  
48th	  Hour	  (n=7)	   12.0	  ±	  2.13	  
	  	  
24th	  Hour	  (n=7)	   15.47	  ±	  0.59	   	  
0.0018	   3.47	  ±	  1.97	   17.6%	  (8.4%	  to	  26.8%)	  
48th	  Hour	  (n=7)	   12.0	  ±	  2.13	  
	  
	  
Outcome in terms of Total Bilirubin Risk Zone Classification 
	   Considering the risk zone classification, the p value of 0.0001 indicates that the 
improvement is significant.  The proportion of subjects in the high risk zone during baseline to 
24th hour went down significantly from 80% to only 28%, while increasing also the low 
intermediate risk and low risk zone classification.  Likewise, comparing baseline to 48th hour, the 
percentage of high risk zone went down significantly from 80.0% to just 9.5%, while increasing 
low intermediate risk and low risk zone. This suggest that the condition of patients significantly 
improved after the 24th and 48th hours of treatment under the LED prototype. 
Table	  6.	  Change	  in	  total	  bilirubin	  risk	  zone	  classification	  
	  Risk	  Zone	   Baseline	   24th	  Hour	   48th	  hour	  
High	   20	  (80.0)	   7	  (28.0)	   2	  (9.5)	  
High	  Intermediate	   5	  (20.0)	   10	  (4)	   6	  (28.6)	  
Low	  Intermediate	   0	  (0.0)	   4	  (16.0)	   5	  (23.8)	  
Low	   0	  (0.0)	   4	  (16.0)	   8	  (38.1)	  
 
Baseline vs 24th hour p = 0.0003 
Baseline vs 48th hour p = 0.0001 
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Interruption to phototherapy 
In terms of feeding interruption, mean duration of breastfeeding was approximately 38 
minutes every 3 hours in 24 hours while in terms of cleaning, the average cleaning time was 7.5 
minutes 4x a day.   Interruption to phototherapy such blood extraction is identical for all patients 
which is 5 minutes once a day.  Turning was done every 2 hours for all patients.  
 
 
 
	  
	  
 
Complications 
No patient experienced complication while on phototherapy treatment.  None of the 
subjects developed hypothermia or hyperthermia while on phototherapy, lowest temperature 
recorded among the subjects was 36.7C, while the highest temperature was 37.5C.   
All subjects had an adequate urine output while on phototherapy treatment under the 
LED prototype.  Results showed that the mean urine output was 4.37cc/kg/hr (SD + 0.80).  The 
highest urine output recorded was 6.5 cc/kg/hr while lowest was 2.9 cc/kg/hr.  No complications 
such as rashes, blisters nor watery stools was noted.   
 
 
 
Table	  7.	  Interruption	  to	  phototherapy	  
Interruption	   Duration	  
Breastfeeding	  	   37.5	  ±	  5.5	   Every	  3	  Hours	  
Cleansing	   7.5	  ±	  0.0	   minutes	  4	  times	  a	  day	  
Blood	  Extraction	   5	   minutes	  a	  day	  
Turning	   2	   Hours	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DISCUSSION 
 
Phototherapy has been the mainstay of management of unconjugated 
hyperbilirubinemia in newborns.  Its efficacy is dependent upon irradiance (light intensity), the 
quality of the light (optimal in the blue-green, 400-550 nm), the exposed body surface area, and 
the duration of exposure. When initiated early, phototherapy can reduce serum bilirubin levels to 
within clinically acceptable levels.  A new type of light source, light emitting diodes (LEDs), for 
phototherapy, have a narrow spectral band of high intensity monochromatic light that overlaps 
the absorption spectrum of bilirubin.10 
Standard phototherapy units deliver a spectral irradiance of 8 to 10 µW/cm2 per nm.  
Intensive phototherapy delivers high levels of irradiance in the 430 to 490-nm band (> 30 
µW/cm2 per nm) to as much of the infant’s surface area as possible.  Special blue tubes provide 
light predominantly in the blue-green spectrum and are highly effective. At wavelengths in the 
blue-green spectrum, light penetrates the skin well and is absorbed maximally by bilirubin.  A 
6% to 20% reduction can be expected in the first 18 to 24 hours of conventional phototherapy. 
Intensive phototherapy can result in a decline of at least 2 to 3 mg/dL (34–51 µmol/L) within 4 to 
6 hours.  A decrease in total serum bilirubin can be noted as early as 2 hours after initiation of 
treatment.  In infants aged 35 weeks of gestation and older, 24 hours of intensive phototherapy 
can result in a 30% to 40% decrease in total serum bilirubin levels.1 
In an unpublished study by Marasigan KL (2014), it was reported that there were about 
2.1% and 2.6% of neonates who were admitted due to hyperbiliribunemia in years 2012 and 
2013, respectively in Ospital ng Makati.  Indirect (Unconjugated) hyperbilirubinemia was found 
to be more common (79.5%) than conjugated hyperbilirubinemia (20.5%) and out of the 91 
recorded cases of indirect hyperbilirubinemia, admitted patients required phototherapy with an 
average duration of 4.64 days and an average rate of decrease in bilirubin was 0.91 mg/dl per 
day using conventional phototherapy that uses blue and white fluorescent bulbs.11   The 
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conventional fluorescent phototherapy in Ospital ng Makati is being administered with an Olidef 
CZ Medphoto 6 Phototherapy Unit which has six fluorescent lamps in four 20 watts day light and 
two blue fluorescent with a lamp life-time of 2,000 hours, emitting a light in the main radiation 
spectrum in the range between 400nm and 550nm, giving an irradiance of 15uW/cm2/nm at 30 
cm distance from lamp box.   
In this pilot study, phototherapy treatment was given using a low cost blue LED 
prototype device that was developed aimed to provide intensive phototherapy that generates 
greater irradiance than the conventional device.  Phototherapy using low-cost LED lights was 
found to be effective in decreasing serum bilirubin levels.  As shown in the results, 52% of 
infants completed phototherapy treatment after 48 hours (Table 1).  Although 48% of subjects 
needed further phototherapy treatment, significant improvement in terms of total bilirubin risk 
zone classification was already achieved after the 24th and 48th hours of treatment under the 
LED prototype (Table 4). Furthermore, none of the neonates from the study who completed 
phototherapy treatment required restarting the phototherapy after 24 hours of having finished 
the treatment.   
Complications associated with phototherapy include loose stools, overheating, 
dehydration due to increased insensible water loss or diarrhea, hyperthermia, skin rashes and 
burns. Maintaining adequate hydration and urine output during phototherapy is important since 
urinary excretion of lumirubin is the principal mechanism by which phototherapy reduces total 
bilirubin.  The American Academy of Pediatrics (AAP) states that intravenous hydration of 
infants receiving phototherapy is not routinely indicated. However some infants with high 
bilirubin levels, who are also mildly dehydrated, may need supplemental fluid intake to correct 
their dehydration. When severe jaundice appears in breastfed infants, the recommendation of 
AAP includes supplementing breast-feeding with formula in an attempt to increase the caloric 
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intake and decrease the enterohepatic circulation.  Continuing fluid supplementation may 
reduce bilirubin by decreasing entrohepatic cycle of bilirubin and increasing urine output.2 
In this pilot study, results showed that there was significant decrease in total serum 
bilirubin level in subjects among both those with and without intravenous fluid supplementation.  
Although the mean difference and % change of TSB from baseline vs 24th and 48th hour seem 
higher in subjects with IVF, 3.89 ± 2.42 mg/dl (18.4%) vs 1.88 ± 1.71 mg/dl (11.3%), baseline 
TSB of these subjects were also higher to begin with.  The baseline mean TSB levels on 
enrollment in supplemented and non-supplemented groups with IVF were 21.15 ± 2.39 mg/dl 
and 16.66 ± 0.84 mg/dl, respectively.  Also, we found that supplementation fluid had no effect 
on the duration of phototherapy.  Most of the subjects with IVF fluid needed to continue 
phototherapy beyond 48 hours given their higher initial TSB.   
In a randomized controlled study by H. Al-Masri in 2012, administration of intravenous 
fluid supplementation during phototherapy on healthy full-term jaundiced infants, showed no 
benefit on reducing the serum bilirubin during phototherapy, and they had similar rates of 
decrease in TSB levels comparing with newborns given only oral feeding.12 
In another controlled study by Z. Easa in 2010 that include fluid supplementation in 
healthy term neonates with non-hemolytic hyperbilirubinemia, intravenous fluid of 1/5 normal 
saline and 5% dextrose was given to 32 neonates while other 32 neonates had no other 
additional fluid. There was no significant difference between the two groups in the rate of 
decreasing TSB or duration of phototherapy hence concluding that administration of extra 
intravenous fluid in jaundiced healthy, term, breastfed neonates have no beneficial effect on the 
rate of serum bilirubin reduction during conventional phototherapy.13 
Side effects like hypothermia and hyperthermia were not found among the subjects in 
this study.  This may be because the enrolled neonates were treated in temperature controlled 
environments with regular monitoring of body temperature.  Since LED does not produce much 
heat, hypothermia may be a problem hence closer monitoring and external heat source may be 
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required.  In a recent report by M. Yurdakok, it was stated that LED phototherapy with high 
irradiances (60-120 µW/cm2/nm) significantly increases body temperature in hyperbilirubinemic 
newborns compared to infants who received conventional phototherapy with fluorescent lamps 
(10-15 µW/cm2/nm) or LED phototherapy (26-60 µW/cm2/nm). Thus the increase in body 
temperature is also reported to be a function of increase of irradiance rather than the type of the 
light source. Hyperthermia might be related to release of pyrogenic cytokines, although effects 
of light with different wave-lengths and irradiances on serum cytokine levels are not known.14   
The LED prototype in this study that emits high irradiance of 84 µW /cm2/nm did not cause 
hyperthermia among the subjects.  Other complications such as loose stools, overheating, 
dehydration and others (burns and rashes) were also not observed.   
 
CONCLUSION / RECOMMENDATION 
 The prototype low cost blue light emitting diode (LED) phototherapy that was developed 
was able to lower total serum bilirubin among healthy term infants with indirect 
hyperbilirubinemia and was safe to use.  However, since this is only a pilot study with limited 
number of subjects, further studies using the prototype LED phototherapy and comparing it with 
the conventional fluorescent phototherapy in the treatment of indirect hyperbilirubinemia are 
needed to test its efficacy.  Evaluation of the efficacy of the prototype LED phototherapy in 
jaundiced neonates with sepsis, hemolytic versus non-hemolytic jaundice and in term versus 
preterm neonates must also be done.  The prototype that was developed has the potential to 
enable phototherapy to be safely and reliably delivered in low-resource settings.   
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APPENDICES  
Appendix A.                                      
Consent Form 
Title: Bilirubin lowering effect and safety of a prototype low cost blue light emitting diode 
(LED) phototherapy device in the treatment of indirect hyperbilirubinemia among healthy 
term infants in Ospital ng Makati: a pilot study. 
 
 Ang katibayang ito ay nagbibigay ng impormasyon ukol sa pagsusuring medikal. Sa oras  
na maunawaan ko ang nilalaman nito, ako ay hihingan ng lagda kung pahihintulutan kong 
mailahok and aking anak.  Nauunawan ko na gagawa ng pagsusuri ukol sa mabuting idudulot 
ng paggamit ng LED phototherapy unit sa paglunas ng paninilaw ng aking anak.   
 Ipinaliwanag sa akin na ang mga ilalahok sa pag-aaral na ito ay yaong mga sanggol na 
ipinanganak na husto sa buwan at walang ibang karamdaman maliban sa pagkakaroon ng 
mataas ng lebel ng bilirubin na nagiging sanhi ng kanilang paninilaw.  Ipinaliwanag sa akin na 
ang LED phototherapy na gagamitin ay nabuo sa tulong ng Ateneo Innovation Center, na ito ay 
naiiba sa karaniwang ginagamit ng ospital na conventional phototherapy gamit ang fluorescent 
light.  Naintindihan ko na layunin ng pag-aaral na ito na subukin ang kakayahan ng LED 
phototherapy upang mapababa ang lebel ng bilirubin ng aking anak.  Aking nauunawaan na sa 
pamamagitan ng paglahok ng aking anak sa pagsusuri, ito ay maaring makadagdag sa 
makasiyensyang pamamaraan sa pagpapabilis ng pagbaba ng paninilaw ng aking anak. 
 Naipaliwanag po sa akin na kukuhanan ng dugo ang aking anak bago magsimula ang 
pagpapailaw, tuwing 24 oras habang nagpapailaw hanggang sa bumaba ang lebel ng paninilaw 
at 24 oras matapos itigil ang pagpapailaw sa kanya upang malaman kung nanatiling mababa 
ang lebel ng bilirubin sa dugo na nagdudulot ng paninilaw at kung sakaling tumaas muli ang 
lebel ng paninilaw ay kakailanganin syang pailawan muli.  Naipaliwanag din po sa akin at aking 
naintihdihan na kakailanganing pailawan ang aking anak sa ilalim ng LED phototherapy ng 
tuloy-tuloy at magagambala lamang ito sa tuwing kailangan nyang dumede, linisan at kuhanan 
ng dugo.  Ipinaliwanag din na kapag bumaba na ang lebel ng bilirubin ng aking anak matapos 
ang 48 hours na pagpapailaw sa ilalim ng LED phototherapy ay isasailalim na siya sa 
pagpapailaw gamit ang kombensyonal na phototherapy na fluorescent hanggang sa maging 
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normal ang lebel ng kanyang bilirubin. Sa aking pagpayag na ilahok ang aking anak sa pag-
aaral na ito ay nauunawaan ko rin ang aking papel na gagampanan na sagutan ang monitoring 
sheet kung saan aking itatala ang oras kung kalian magagambala ang pagpapailaw sa kanya sa 
ilalim ng LED phototherapy tulad ng oras ng pagpapadede, pagpapaligo at pagkuha sa kanya 
upang kuhanan ng dugo.  
 Naunawaan ko na posibleng magkaroon ng mga di inaasahang reaskyon sa bata katulad 
ng pamumula ng balat o pagkakaroon ng rashes, pagtatae, paglalagnat, pagkatuyot o 
dehydration.  Ganunpaman, naunawaan ko na may masinsinang pagbabantay na gagawin 
upang maiwasan ang mga posibleng komplikasyon na nabanggit.  Kung magkakaroon man ng 
anumang reaksyon dulot ng pagsusuring ito ay alam ko na bibigyan ito ng kaukulang paglunas 
ng mga doktor. 
 Ipinaalam rin sa akin na wala akong makukuhang pinansyal na suporta o pera sa pagsali 
sa pag-aaral na ito.  Tanging libreng serbisyo ng mga doktor at paggamit ng mga pasilidad ng 
Ospital gaya ng phototherapy unit ang aming makukuha.  Naipaliwanag rin sa akin na ang mga 
impormasyon tungkol sa aking anak ukol sa pagsali n’ya sa pag-aaral na ito ay hindi ibubunyag 
at mananatiling kumpidensyal na naaayon sa batas, liban sa gumagawa ng pagsusuring ito. 
Ang mga imposmasyon mula sa pagsusuring ito ay maaring mailathala o maibigay sa ibang 
taong gumagawa ng pagsusuri, ngunit ang pagkakakilanlan sa akin at sa aking anak ay hindi 
ibubunyag. 
 Alam ko na ang pagsali sa pagsusuri ay dapat kusang-loob. Maaari kong bawiin ang 
pakikilahok sa pagsusuri ng aking anak kahit anong oras at hindi magbabago ang pagbibigay 
ng lunas sa aking anak.  Lahat ng aking katanungan ukol sa pagsusuring ito ay nasagot ng may 
katiyakan at lubos kong nauunawaan. Binigyan rin ako ng sapat na oras para pag-isipan ang 
pagbibigay ng aking pahintulot. 
 Kung ako man ay may katanungan, maaari kong kausapin si Dr. Vanessa Calabia sa 
telepono bilang: 8826316 loc 258 o cellphone: 09255842009 o si Dr. Viel Bagunu sa telepono 
bilang: 8826316 loc 258 o cellphone: 09256827835.  At kung ako man ay may katanungan sa 
kung paano nabuo ang LED phototherapy ay maari kong kausapin si Engr. Paul Cabacungan 
ng Ateneo Innovation Center sa telepono bilang: 9272147 o cellphone: 09183860216. 
 Sa aking paglagda ay ipinapahiwatig nitong nabasa at naunawaan ko ang mga nakatala  
at kusang-loob na pinahihintulutan ko ang aking anak na lumahok sa naturang pag-aaral. 
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_____________________________    _______________ 
Pangalan ng pasyente       Petsa 
 
______________________________            ________________ 
Pangalan at lagda ng magulang     Petsa 
 
______________________________    ________________  
Pangalan at lagda ng saksi      Petsa 
 
________________________________   ________________  
Pangalan at lagda ng kumukuha ng pagsang-ayon  Petsa  
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Appedix B. 
NOMOGRAM 
 
Figure	  1:	  NOMOGRAM	  Risk	  designation	  of	  term	  and	  near-­‐term	  well	  newborns	  based	  on	  their	  hour-­‐specific	  serum	  bilirubin	  values.	  The	  high-­‐risk	  zone	  is	  subdivided	  by	  the	  95th	  percentile	  track.	  The	  intermediate	  -­‐risk	  zone	  is	  subdivided	  into	  upper	  and	  lower	  risk	  zones	  by	  the	  75th	  percentile	  track.	  The	  low-­‐risk	  zone	  has	  been	  electively	  and	  statistically	  defined	  by	  the	  40th	  percentile	  track.	  (From	  Bhutani	  VK,	  Johnson	  L,	  Sivieri	  EM:	  Predictive	  ability	  of	  a	  predischarge	  hour-­‐specific	  serum	  bilirubin	  for	  subsequent	  significant	  hyperbilirubinemia	  in	  healthy	  term	  and	  near-­‐term	  newborns,	  Pediatrics	  103:6–14,	  1999.)	  SOURCE:	  Nelson	  Textbook	  of	  Pediatrics	  19th	  edition 
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Appendix C. 
 
Case report form 
 
 
Name of Participant: ________________________ Patient number: ________ 
 
Age /sex:____________  Date/Time of birth:______________________ 
 
Patient’s blood type: ________ Mother’s blood type: _________ 
 
Baseline TSB: ______________ Feeding: _____________ 
 
Phototherapy:  
Date/time started: _____________      Date/time ended: __________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phototherapy 
(Hours) 
TSB 
(mg/dL) 
Risk Zone (based on hour-
specific normogram) 
Complications 
Rash Blister Watery 
stool 
Others 
24h       
48h       
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Appendix D.   
 
Mother Data Collection Form 
 
 Name of Patient: ________________________________________________ 
 
 Breastfeeding Cleaning Turning Blood extraction 
Date/time     
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Appendix E.      
Patient Monitoring Form 
 
Name of Patient: ________________________________________________ 
 
Date/time Weight Temperature Urine output 
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Appendix F. 
 
PHOTOTHERAPY LIGHT FOR JAUNDICE TREATMENT 
Vanessa Marie V. Calabia MD*, Gregory L. Tangonan, Ph.D.**., Jeremy E. De Guzman MD*, 
MBA, ,  Paul M. Cabacungan, MS** Ivan B. Culaba, MS*** 
*Ospital ng Makati 
**Ateneo Innovation Center, Ateneo de Manila University 
***Department of Physics, Ateneo de Manila University 
 
Neonatal jaundice occurs in 25% to 50% of term newborns, and in a larger proportion of 
preterm newborns, in the first two weeks of life.  It is a benign transient physiological event in 
the majority of newborns but can cause irreversible brain damage and kernicterus in some 
infants if the serum bilirubin levels are very high. Various mechanisms involved in producing this 
'physiological' increase in serum total bilirubin include increased production of bilirubin due to 
lysis of red blood cells, decreased ability of liver cells to clear bilirubin and increased 
enterohepatic circulation. Any condition that further increases bilirubin production or alters the 
transport or metabolism of bilirubin increases the severity of the physiological jaundice (2).  
Phototherapy is the most frequently used treatment when serum bilirubin levels exceed 
physiological limits. To initiate phototherapy without delay is the most important intervention for 
infants with severe hyperbilirubinemia.  Phototherapy converts bilirubin into water soluble photo-
products that can bypass the hepatic conjugating system and be excreted without further 
metabolism. The clinical response to phototherapy depends on the efficacy of the phototherapy 
device, as well as the infant’s rates of bilirubin production and elimination (1).   Phototherapy, 
despite being the recommended standard of treatment for hyperbilirubinemia in newborns, may 
not be available in developing countries because the devices and replacement bulbs are often 
too expensive. 
Phototherapy can be delivered using several types of conventional light sources, 
including daylight, white or blue fluorescent bulbs and filtered halogen bulbs.  The efficacy and 
ability of these light sources to provide intensive phototherapy varies widely and some may be 
limited because of the inability to keep them close to the infant due to high heat production and 
unstable broad wavelength light output. In recent years, a new type of light source, light-emitting 
diodes (LEDs) have been developed and studied as possible light sources for the phototherapy 
of neonatal jaundice. LEDs are power efficient, portable devices with low heat production, light 
in weight and have a longer lifetime (2).  Blue LEDs emit a high intensity narrow band of blue 
light overlapping the peak spectrum of bilirubin breakdown resulting in potentially shorter 
treatment times.  These characteristics of LEDs make them an optimal light sources for a 
phototherapy device (3).    
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Specifications of the light source a. Emission spectrum of the LED lamp 
 
A Spectro-Vis Plus (Vernier) was used to determine the spectrum of the LED lamps. 
Figure 1 below shows the peak intensity at 462.1 nm which falls on the blue region of 
the visible spectrum of light. The range of the emission spectrum was found to be 
462.1-476.4 nm. This range falls within the most effective range (460-490 nm) for 
phototherapy of jaundice [3]. The instrument used in determining the emission 
spectrum of the lamps is shown in Figure 2. 
 
 
Figure 1. The emission spectrum of the light sour 
 
 
Figure 2. The Spectro-Vis Plus used in determining the emission spectrum 
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b. Irradiance  
 
The intensity of the LED was 12W/m2 measured using a light intensity meter.      
The calculated value of the irradiance was 84 µW/cm2 /nm. This value is almost 
three times higher than the minimum required irradiance (30 at µW/cm2 /nm) at 1-m 
distance. Note that protocol for clinical trial is only 30 cm and therefore the irradiance 
of this light source is sufficient for phototherapy. The calculation of the irradiance is 
shown below. Figure 3 shows the measurement of the intensity. 
 
       Irradiance = measured intensity (microwatt/ square cm) / range of wavelength 
                   Irradiance = {(12 W/ m2) * (106 µW / watt) * [(1 m2 /104cm2)]}               
                                                 / {476.4 nm– 462.1 nm} 
                                          =84 µW /cm2/nm 
            
 
Figure 3. Measurement of the intensity of the LED lamp 
 c. Electrical power requirement 
 
Each lamp is operated at 220 V at 3 W. The total power requirement for 20 lamps is 
60 W. To maintain low temperature of operation a 10-W computer fan is used for 
ventilation.  
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The Phototherapy Equipment 
Photos of the phototherapy equipment are shown in Figures 4, 5 and 6. There are 20 
pieces of blue LED lamps, connected in parallel, for a total power rating of 60 W.  The assembly 
of the lamps is shown on Figure 4.   
        
Figure 4. Assembly of the 20 pieces of blue LED lamps. 
There is a 2-A fuse for protection due to overcurrent. Ten lamps are turned on/off by a switch 
and the other ten lamps are turned on/off by a separate switch.  A 10-W computer fan was 
installed for cooling the light casing, ventilation and a safety feature to exhaust any harmful 
fumes that the circuit might generate.  This fan operates even when the lamps are turned off. 
There is a main power switch which controls all the electrical parts. The top cover has 2-mm 
diameter perforations, distanced 1 cm apart, which allow warm air to escape from the case. The 
interior part of the casing is lined with silver foil reflector sheet to maximize the illumination to 
the target area. There is a clear plastic cover to safely secure the bulbs in place.  Hinges were 
attached at the sides of the light casing for easy maintenance and/or trouble shooting. Figure 5 
shows the casing of the phototherapy equipment. 
 
                                  Figure 5. The casing of the light source 
The unit is designed in such a way that the whole light casing can be tilted from side to side, the 
metallic pipe stand height can be adjusted, the whole unit can be rolled through its wheels for 
mobility/easy handling. Figure 6 shows the complete phototherapy equipment.  The total cost for 
the development of the prototype equipment was approximately  PhP 20,000.00 
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Figure 6. The complete phototherapy equipment 
The total power consumption of this prototype is 75 watts which is less than one fifth of the 
commercial phototherapy light (about 400 watts) that uses fluorescent tubes.  This prototype 
unit can also powered by photovoltaic cells (solar panels).  For a 100-watt solar panel at four-
hours of sunlight, it can operate for five-hours with all light bulbs continuously switched on. It is 
designed in such a way that at it can also operate at half power and twice the time. 
An internal continuous test-run was conducted with all the lamps turned on for 7-hours, 
24-hours, and 72-hours. There was no notable degradation of the quality of the lamp. 
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